Highlights of Recent Hematology and Oncology National Meetings

This program happened in the past, and no dates are currently scheduled.

Select this button to navigate the sections of this page

Conference ID

J6138-18

Overview

This program is designed to bring information acquired at national meetings back to the central Pennsylvania area for physicians and other health care professionals to use in their daily clinical practices. The topics chosen represent material presented at the ASCO 2017 National Meeting, the 2016 San Antonio Breast Cancer Conference and the 2016 ASH Annual Meeting. This presentation is not endorsed by or affiliated with SABCS, ASH or ASCO.

Audience

Hematology and oncology physicians and other health care professionals.

Goals

  • Present the latest scientific information from the national meetings
  • Review treatment and research information
  • Assess implications for clinical practice

Conference Objectives

  • Describe the goals and status of cancer care in the USA as discussed in ASCO and AACR
  • Describe aspirations and progress of Penn State Cancer Institute toward becoming an NCI-designated cancer center.
  • Describe the role of immune checkpoint inhibitors
  • Review the precise choice of targeted agent(s), and the changing dynamics in the integration of chemotherapy
  • Evaluate the interaction of chemotherapy, radiation and targeted therapies in the management of squamous cell carcinomas of the head and neck
  • Review the role of targeted therapies in the management of thyroid cancer
  • Describe the effectiveness and toxicities of immunobiologic therapies for melanoma and other solid tumors
  • Explain the mechanism of action of CDK4/CD6 inhibitors in regulating the cell cycle
  • Compare the data of activity and toxicities on combining palbociclib, ribociclib and abemaciclib with antiestrogenic agents in the treatment of metastatic breast cancer
  • Explain the role of endocrine therapies and other targeted agents in the management of ER-positive breast cancer
  • Interpret how biomarkers can serve as prognostic and predictive factors in breast cancer
  • Assess how robust biomarkers may help to define targeted therapy
  • Review the guidelines for selecting patients for adjuvant therapy
  • Discuss the role of immunotherapy and new drugs
  • Appropriately utilize currently approved treatments for advanced or metastatic urothelial bladder cancer to optimize patient outcomes
  • Incorporate neoadjuvant chemotherapy into the multidisciplinary management of patients with advanced or metastatic urothelial bladder cancer
  • Evaluate the role of immunotherapy and other agents in the management of ovarian cancer
  • Explain what factors determine the role of radiation therapy and specific chemotherapies in the management of endometrial cancers in patients
  • Examine the increasing treatment options for chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)
  • Evaluate management of common toxicities in cancer patients
  • Explain the responsibilities of enhancing quality-of-life in cancer survivors
  • Explain how the Centers for Medicare and Medicaid Services (CMS) regulations are affecting treatment of patients and practice management
  • Appraise the arguments for and against clinical pathways

Credit

AMA

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Penn State College of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses Using AMA Credit

Nurses will receive a certificate from Penn State College of Medicine verifying their participation in 6.75 hours of approved continuing medical education. Continuing education activities which are approved by accredited institutions of higher education and that are relevant to patient care or professional nursing meet the requirements of mandatory continuing education for registered nurses in Pennsylvania, as required by the Pennsylvania State Board of Nursing. The Board of Nursing recommends that nurses retain their certificates for a period of at least five years. Additional information is available through the Pennsylvania State Board of Nursing.

ACPE

The ACPE logo, black vaguely Romanic text with "AC" stacked directly on top of "PE," surrounded by a black-box border.Penn State Health Milton S. Hershey Medical Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned the Universal Activity Number of 0322-0000-17-019-L01-P. It has been approved for 5.5 Contact hours or 0.55 CEUs of continuing pharmacy education credit in states that recognize ACPE providers. The attendee list will be uploaded into CPE Monitor approximately one week after completion of the program. Statements of credit indicated in contact hours and CEUs will be available through CPE Monitor. Successful completion includes signing in at registration with personal NABP number and date of birth, attending the entire session for which credit is claimed, and completing the activity evaluation. Penn State Health Milton S. Hershey Medical Center complies with the Accreditation Standards for Continuing Education.

Agenda

  • 8 a.m. | Check-in/Continental Breakfast/Exhibits
  • 8:30 a.m. | Overview – Perspectives in Cancer Control: Locally and Nationally
    Ray Hohl, MD, PhD
  • 9 a.m. | ASCO Round Table (3 topics)
    What’s Hot in Lung Cancer?

    Chandra Belani, MD

    Head and Neck Cancer Treatments: Any Progress?
    Salah Almokadem, MD

    Melanoma, Sarcoma, Immunotherapy — A Potpourri
    Joseph Drabick, MD

  • 10:15 a.m. | Break/Exhibits
  • 10:45 a.m. | SABCS Round Table (3 topics)
    Coming of Age of CD4/CD6 Inhibition in Breast Cancer
    Cristina Truica, MD

    Hormones and Other Targeted Agents for Breast Cancer
    Harold A. Harvey, MD

    Why Biomarkers Matter in Breast Cancer
    Kim Leitzel, MSc

  • 12:15 p.m. | Lunch and Guest Speaker
    Update and Future Directions in the Immunotherapy of Melanoma and Non-Melanoma Skin Cancer
    William H. Sharfman, MD
  • 1:30 p.m. | ASCO Round Table (2 topics)
    GU Malignancies: Unravelling the Biology of Bladder Cancer
    Monika Joshi, MD

    GYN Malignancies: What’s New for the Medical Oncologist in the Management of Ovarian and Endometrial Cancers?
    Ricardo Carter, MD

  • 2:15 p.m. | Break/Exhibits
  • 2:30 p.m. | ASH Round Table (2 topics)
    Lymphoma and Leukemia Update

    Witold Rybka, MD

    Palliative Care and Survivorship Issues
    Suhail Ali, MD

  • 3:30 p.m. | New Regulations and Practice Management
    Edward Balaban, DO
  • 4 p.m. | Open Discussion and Adjournment

Faculty

Suhail Ali, MD
Associate Professor of Medicine
Lebanon VA Medical Center
Lebanon, PA

Salah Almokadem, MD
Assistant Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Edward Balaban, DO
Adjunct Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Chandra Belani, MD
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Ricardo Carter, MD
Private Practice
Hematology/Oncology Cancer Program Director Geisinger Lewistown Hospital
Lewistown, PA

Leah Cream, MD
Assistant Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Joseph Drabick, MD
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Harold A. Harvey, MD
Course Director
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Ray Hohl, MD, PhD
Professor of Medicine and Pharmacology
Director of Penn State Cancer Institute
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Monika Joshi, MD
Assistant Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Kim Leitzel, MSc
Senior Research Support Associate
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

William H. Sharfman, MD
Mary Jo Rogers
Professor of Cancer Immunology and Melanoma Research
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Cristina Truica, MD
Associate Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Witold Rybka, MD
Professor of Medicine
Penn State Health Milton S. Hershey Medical Center
Penn State College of Medicine

Fee

Fee includes instruction, all listed meals and online handout materials $40 per person $25 Penn State Health Milton S. Hershey Employees Registrations received after Aug. 24, 2017, will incur a $25 late fee.

Cancellation Policy

No refunds after Aug. 21, 2017.

Please notify the Continuing Education Office if you need to cancel so that others may register.

The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances. If a program is canceled or postponed, the University will refund registration fees but cannot be held responsible for any related costs, charges, or expenses, including cancellation/change charges assessed by airlines or travel agencies. Preregistered participants will be notified if a program is filled or canceled.

Access (ADA)

Penn State encourages persons with disabilities to participate in its programs and activities. If you anticipate needing any type of special accommodation or have questions about the physical access provided, please contact Continuing Education at least one week in advance of your participation or visit.

Changes

Content and speakers for all programs are subject to change. Registrants will be notified of any significant updates.

Disclosure and Conflict of Interest (COI and educational balance)

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Complete faculty disclosure will be provided to program participants at the beginning of the activity.

University Nondiscrimination Policy

This publication is available in alternative media on request. The Pennsylvania State University is committed to the policy that all persons shall have equal access to programs, facilities, admission, and employment without regard to personal characteristics not related to ability, performance, or qualifications as determined by University policy or by state or federal authorities. It is the policy of the University to maintain an academic and work environment free of discrimination, including harassment. The Pennsylvania State University prohibits discrimination and harassment against any person because of age, ancestry, color, disability or handicap, genetic information, national origin, race, religious creed, sex, sexual orientation, gender identity, or veteran status and retaliation due to the reporting of discrimination or harassment. Discrimination, harassment, or retaliation against faculty, staff, or students will not be tolerated at The Pennsylvania State University. Direct all inquiries regarding the Nondiscrimination Policy to the Affirmative Action Director, The Pennsylvania State University, 328 Boucke Building, University Park, PA 16802-5901; tel 814-863-0471/TTY. US M.Ed. J6138-18

Jump to ...